Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
暂无分享,去创建一个
T. Okumura | N. Enomoto | A. Torii | T. Shimosegawa | Y. Naito | K. Koike | S. Fukudo | H. Miwa | T. Kamiya | H. Kaneko | M. Inamori | M. Kanazawa | Ken Sato | K. Fujimoto | A. Shiotani | K. Matsueda | R. Hokari | Y. Fujikawa | Y. Okuyama | Tastuhiro Masaoka | Motoyori Kanazawa
[1] P. Whorwell,et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. , 2020, Gastroenterology.
[2] W. Shih,et al. Negative Events During Adulthood are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] A. Carrasco-Labra,et al. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D) , 2019, Gastroenterology.
[4] A. Carrasco-Labra,et al. American Gastroenterological Association Guideline on Mild-to-Moderate Ulcerative Colitis on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). , 2019, Gastroenterology.
[5] D. Schuppan,et al. Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. , 2019, Gastroenterology.
[6] M. Surette,et al. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. , 2019, Gastroenterology.
[7] Jennifer S. Lin,et al. The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods , 2019, Annals of Internal Medicine.
[8] P. Moayyedi,et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis , 2019, Gut.
[9] Y. Kinoshita,et al. Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment. , 2019, Allergology international : official journal of the Japanese Society of Allergology.
[10] Kehu Yang,et al. Assessment of the Quality and Content of Clinical Practice Guidelines on Irritable Bowel Syndrome Using the AGREE II Instrument , 2019, Digestion.
[11] P. Higgins,et al. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. , 2019, The American journal of gastroenterology.
[12] M. Camilleri,et al. Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[13] P. Moayyedi,et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS) , 2019, Journal of the Canadian Association of Gastroenterology.
[14] G. Mullin,et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data , 2019, BMC Complementary and Alternative Medicine.
[15] Justin C.Y. Wu,et al. Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis , 2019, Therapeutic advances in gastroenterology.
[16] U. Ghoshal,et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. , 2019, Gastroenterology.
[17] H. Matsumoto,et al. Efficacy of Mirtazapine on Irritable Bowel Syndrome with Anxiety and Depression: A Case Study. , 2018, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[18] G. Zheng,et al. Association between SERT insertion/deletion polymorphism and the risk of irritable bowel syndrome: A meta-analysis based on 7039 subjects. , 2018, Gene.
[19] P. Moayyedi,et al. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. , 2018, Gastroenterology.
[20] F. Azpiroz,et al. Probiotics in irritable bowel syndrome: Where are we? , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[21] P. Moayyedi,et al. Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome , 2018, Alimentary pharmacology & therapeutics.
[22] E. Zhao,et al. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[23] W. Yeo,et al. Systematic review with meta‐analysis: The association between post‐traumatic stress disorder and irritable bowel syndrome , 2018, Journal of gastroenterology and hepatology.
[24] M. Currie,et al. A randomized controlled and long‐term linaclotide study of irritable bowel syndrome with constipation patients in Japan , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[25] M. Camilleri,et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. , 2018, The lancet. Gastroenterology & hepatology.
[26] L. Hansen,et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study , 2018, Gut.
[27] A. Awaisu,et al. Efficacy and safety of laxatives for chronic constipation in long‐term care settings: A systematic review , 2018, Journal of clinical pharmacy and therapeutics.
[28] Lingping Zhu,et al. Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis , 2018, Evidence-based complementary and alternative medicine : eCAM.
[29] P. Whorwell,et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence‐based international consensus , 2018, Alimentary pharmacology & therapeutics.
[30] N. Ishimura,et al. Celiac disease in non-clinical populations of Japan , 2018, Journal of Gastroenterology.
[31] Lin Chang,et al. FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.
[32] P. Schoenfeld,et al. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis , 2018, The American Journal of Gastroenterology.
[33] P. Dupont,et al. Influence of Uncertain Anticipation on Brain Responses to Aversive Rectal Distension in Patients With Irritable Bowel Syndrome , 2017, Psychosomatic medicine.
[34] N. Waszkiewicz,et al. Antidepressants for irritable bowel syndrome—A systematic review , 2017, Pharmacological reports : PR.
[35] M. Camilleri,et al. Pharmacotherapy for Irritable Bowel Syndrome , 2017, Journal of clinical medicine.
[36] P. Dupont,et al. Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome , 2017, Scientific Reports.
[37] U. Ghoshal,et al. Mapping of Brain Activations to Rectal Balloon Distension Stimuli in Male Patients with Irritable Bowel Syndrome Using Functional Magnetic Resonance Imaging , 2017, Journal of neurogastroenterology and motility.
[38] M. Hattori,et al. Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome , 2017, Digestion.
[39] M. Camilleri,et al. Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[40] T. Kanai,et al. Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome , 2017, Intestinal research.
[41] Lin Lin,et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials , 2017, PloS one.
[42] S. Hollon,et al. Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. , 2017, Clinical psychology review.
[43] B. Feng,et al. Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article , 2017, Anesthesiology and pain medicine.
[44] C. Lam,et al. Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable Bowel Syndrome Revealed by MRI , 2016, The American Journal of Gastroenterology.
[45] P. Schoenfeld,et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea , 2016, The American Journal of Gastroenterology.
[46] M. Mínguez,et al. Use of polyethylene glycol in functional constipation and fecal impaction. , 2016, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[47] W. Shih,et al. Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response , 2016, Psychoneuroendocrinology.
[48] M. Lomer,et al. British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). , 2016, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.
[49] S. Fukudo,et al. Dai-Kenchu-To, a Herbal Medicine, Attenuates Colorectal Distention-induced Visceromotor Responses in Rats , 2016, Journal of neurogastroenterology and motility.
[50] P. Dupont,et al. Differential Activation in Amygdala and Plasma Noradrenaline during Colorectal Distention by Administration of Corticotropin-Releasing Hormone between Healthy Individuals and Patients with Irritable Bowel Syndrome , 2016, PloS one.
[51] D. Drossman. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. , 2016, Gastroenterology.
[52] P. Whorwell,et al. Centrally Mediated Disorders of Gastrointestinal Pain. , 2016, Gastroenterology.
[53] Xiangfeng Wang,et al. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2016, Mayo Clinic proceedings.
[54] P. Carmeliet,et al. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. , 2016, Gastroenterology.
[55] S. Fukudo,et al. Associations between Single-Nucleotide Polymorphisms in Corticotropin-Releasing Hormone-Related Genes and Irritable Bowel Syndrome , 2016, PLoS ONE.
[56] T. Okumura,et al. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. , 2016, Gastroenterology.
[57] Y. Yamaguchi-Kabata,et al. Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome , 2016, PloS one.
[58] T. Okumura,et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study , 2016, Journal of Gastroenterology.
[59] L. Turner,et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. , 2016, The New England journal of medicine.
[60] Cheng-Li Lin,et al. Irritable Bowel Syndrome Is Associated with an Increased Risk of Dementia: A Nationwide Population-Based Study , 2016, PloS one.
[61] L. Böhn,et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. , 2015, Gastroenterology.
[62] M. Camilleri,et al. Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis , 2015, Gut.
[63] Lin Lin,et al. Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis , 2015, PloS one.
[64] C. Manichanh,et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome , 2015, Scientific Reports.
[65] R. Spiller,et al. Irritable bowel syndrome , 2015, Nature Reviews Disease Primers.
[66] A. Ford,et al. Systematic review with meta‐analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea , 2015, Alimentary pharmacology & therapeutics.
[67] J. Guardiola,et al. Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea , 2015, Alimentary pharmacology & therapeutics.
[68] R. Spiller,et al. A meta‐analysis of immunogenetic Case–Control Association Studies in irritable bowel syndrome , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[69] S. Kim,et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[70] E. Mayer,et al. Serotonin Transporter Gene Polymorphism Modulates Activity and Connectivity within an Emotional Arousal Network of Healthy Men during an Aversive Visceral Stimulus , 2015, PloS one.
[71] A. Zinsmeister,et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea‐predominant irritable bowel syndrome , 2015, Alimentary pharmacology & therapeutics.
[72] Jacob E. Kurlander,et al. A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS , 2015, The American Journal of Gastroenterology.
[73] G. Ringström,et al. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. , 2015, World journal of gastroenterology.
[74] L. Brandt,et al. Is Fecal Microbiota Transplantation the Answer for Irritable Bowel Syndrome? A Single-Center Experience , 2014, The American Journal of Gastroenterology.
[75] P. Moayyedi,et al. Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis , 2014, The American Journal of Gastroenterology.
[76] P. Moayyedi,et al. The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis , 2014, The American Journal of Gastroenterology.
[77] H. Zhang,et al. Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety. , 2014, World journal of gastroenterology.
[78] N. Bunnett. Neuro‐humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract , 2014, The Journal of physiology.
[79] S. Fukudo,et al. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[80] M. Camilleri,et al. Systematic review with meta‐analysis: highly selective 5‐HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation , 2014, Alimentary pharmacology & therapeutics.
[81] T. Oka,et al. Effects of Kampo on functional gastrointestinal disorders , 2014, BioPsychoSocial Medicine.
[82] F. Sung,et al. Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan , 2014, European Journal of Epidemiology.
[83] I. Hall,et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea , 2013, Gut.
[84] S. Fukudo. Stress and visceral pain: Focusing on irritable bowel syndrome , 2013, PAIN®.
[85] Y. Jeen,et al. [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. , 2013, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[86] R. Khanna,et al. Peppermint Oil for the Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis , 2013, Journal of clinical gastroenterology.
[87] M. Daly,et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts , 2013, Gut.
[88] A. Zinsmeister,et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[89] T. Timpka,et al. Patients with irritable bowel syndrome are more burdened by co-morbidity and worry about serious diseases than healthy controls- eight years follow-up of IBS patients in primary care , 2013, BMC Public Health.
[90] J. Almenoff,et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. , 2013, Gastroenterology.
[91] V. Verhasselt,et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation , 2013, Gut.
[92] R. Chapman,et al. Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome , 2013, The American Journal of Gastroenterology.
[93] T. Kutlu,et al. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment , 2013, Journal of neurogastroenterology and motility.
[94] H. Mushiake,et al. Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on FMRI and dynamic causal modeling. , 2012, Gastroenterology.
[95] A. Ford,et al. Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.
[96] S. Fukudo,et al. Corticotropin-Releasing Hormone Receptor 1 Gene Variants in Irritable Bowel Syndrome , 2012, PloS one.
[97] A. Lembo,et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS , 2012, Alimentary pharmacology & therapeutics.
[98] A. Ford,et al. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[99] S. Ishihara,et al. Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multi-center study utilizing colonoscopy , 2012, Journal of Gastroenterology.
[100] W. Chey,et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation , 2012, Alimentary pharmacology & therapeutics.
[101] J. Tack,et al. Colonic Transit Time and IBS Symptoms: What's the Link? , 2012, The American Journal of Gastroenterology.
[102] L. Öhman,et al. Altered Levels of Fecal Chromogranins and Secretogranins in IBS: Relevance for Pathophysiology and Symptoms? , 2012, The American Journal of Gastroenterology.
[103] N. Talley,et al. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study , 2012, Gut.
[104] W. Chey,et al. The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.
[105] P. Whorwell,et al. Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report , 2011, The American Journal of Gastroenterology.
[106] K. Whelan,et al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. , 2011, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.
[107] N. D. de Wit,et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. , 2011, The Cochrane database of systematic reviews.
[108] S. Fukudo,et al. Effect of 5‐HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[109] B. Kim,et al. Trimebutine as a modulator of gastrointestinal motility , 2011, Archives of pharmacal research.
[110] M. Kamm,et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[111] M. Hongo,et al. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo‐controlled and dose‐finding study , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[112] M. Simrén,et al. Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial , 2011, The American Journal of Gastroenterology.
[113] M. Camilleri,et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. , 2011, Inflammatory bowel diseases.
[114] B. Jiang,et al. Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case–control study , 2011, International Journal of Colorectal Disease.
[115] K. Tominaga,et al. Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[116] H. Sørensen,et al. Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study , 2011, British Journal of Cancer.
[117] W. Chey,et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. , 2011, The New England journal of medicine.
[118] B. Cash,et al. The Incidence and Gastrointestinal Infectious Risk of Functional Gastrointestinal Disorders in a Healthy US Adult Population , 2011, The American Journal of Gastroenterology.
[119] A. Zinsmeister,et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. , 2010, Gastroenterology.
[120] M. Forsting,et al. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. , 2010, Gastroenterology.
[121] Lin Chang,et al. Diagnosis and management of IBS , 2010, Nature Reviews Gastroenterology &Hepatology.
[122] B. Spiegel,et al. Meta‐analysis: do irritable bowel syndrome symptoms vary between men and women? , 2010, Alimentary pharmacology & therapeutics.
[123] M. Hongo,et al. Effect of Autogenic Training on General Improvement in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial , 2010, Applied psychophysiology and biofeedback.
[124] O. Nielsen,et al. The safety of osmotically acting cathartics in colonic cleansing , 2010, Nature Reviews Gastroenterology &Hepatology.
[125] P. Shekelle,et al. The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of Methods , 2010, Annals of Internal Medicine.
[126] Eun Soo Kim,et al. Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: Focus on pain perception , 2010, Journal of gastroenterology and hepatology.
[127] Kirsten Tillisch,et al. Regional gray matter density changes in brains of patients with irritable bowel syndrome. , 2010, Gastroenterology.
[128] G. Wall,et al. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. , 2010, Clinical therapeutics.
[129] J. Belsey,et al. Systematic review and meta analysis: polyethylene glycol in adults with non‐organic constipation , 2010, International journal of clinical practice.
[130] K. Tominaga,et al. Prevalence of overlaps between GERD, FD and IBS and impact on health‐related quality of life , 2010, Journal of gastroenterology and hepatology.
[131] M. Pimentel. An Evidence-Based Treatment Algorithm for IBS Based on a Bacterial/SIBO Hypothesis: Part 2 , 2010, The American Journal of Gastroenterology.
[132] A. Zinsmeister,et al. Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. , 2010, American journal of physiology. Gastrointestinal and liver physiology.
[133] K. Davis,et al. Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. , 2010, Gastroenterology.
[134] A. Garg,et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. , 2010, Gastroenterology.
[135] A. Attili,et al. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial. , 2010, European review for medical and pharmacological sciences.
[136] M. Kamm,et al. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients With Chronic Constipation , 2010, The American Journal of Gastroenterology.
[137] D. Drossman. Beyond Tricyclics: New Ideas for Treating Patients With Painful and Refractory Functional Gastrointestinal Symptoms , 2009, The American Journal of Gastroenterology.
[138] S. Fukudo,et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[139] R. A’Hern,et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.
[140] Kazuhiko Yanai,et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention , 2009, NeuroImage.
[141] P. Whorwell,et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial , 2009, BMJ : British Medical Journal.
[142] B. P. Brennan,et al. Duloxetine in the treatment of irritable bowel syndrome: an open‐label pilot study , 2009, Human psychopharmacology.
[143] R. Moss‐Morris,et al. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care , 2009, Psychological Medicine.
[144] P. Moayyedi,et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. , 2009, Archives of internal medicine.
[145] B. Neri,et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.
[146] E. Quigley,et al. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). , 2009, Journal of gastrointestinal and liver diseases : JGLD.
[147] G. Gibson,et al. Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.
[148] D. Drossman,et al. Atypical Antipsychotic Quetiapine in the Management of Severe Refractory Functional Gastrointestinal Disorders , 2009, Digestive Diseases and Sciences.
[149] Rafael Perera,et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome , 2009, BMC gastroenterology.
[150] D. Tester,et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[151] P. Moayyedi,et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review , 2008, Gut.
[152] P. Moayyedi,et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.
[153] T. Timpka,et al. Self-Reported Use of Pharmaceuticals Among Patients With Irritable Bowel Syndrome in Primary Care , 2008, Journal of managed care pharmacy : JMCP.
[154] D. Drossman,et al. Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits , 2008, The American Journal of Gastroenterology.
[155] R. Spiller. Review article: probiotics and prebiotics in irritable bowel syndrome , 2008, Alimentary pharmacology & therapeutics.
[156] M. Camilleri,et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[157] M. Hongo,et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome , 2008, Scandinavian journal of gastroenterology.
[158] P. Whorwell,et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. , 2007, The Cochrane database of systematic reviews.
[159] W. Chey,et al. The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review , 2007, The American Journal of Gastroenterology.
[160] Lin Chang,et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA Irritable Bowel Syndrome : Current Approach to Symptoms , Evaluation , and Treatment , 2022 .
[161] M. Thabane,et al. Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome , 2007, Alimentary pharmacology & therapeutics.
[162] S. Gordon,et al. A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of 0.5 mg and 1 mg Alosetron in Women With Severe Diarrhea-predominant IBS , 2007, The American Journal of Gastroenterology.
[163] E. Blanchard,et al. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. , 2007, Gastroenterology.
[164] B. Spiegel,et al. Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome , 2007, Alimentary pharmacology & therapeutics.
[165] M. Camilleri,et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis , 2007 .
[166] Khek Yu Ho,et al. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls , 2006, Pain.
[167] M. Pimentel,et al. The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome , 2006, Annals of Internal Medicine.
[168] M. Içer,et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome , 2006, Journal of gastroenterology and hepatology.
[169] K. Haruma,et al. [Ultrasonographic assessment of sigmoid colon in patients with irritable bowel syndrome]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[170] M. Pimentel,et al. Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study , 2006, Digestive Diseases and Sciences.
[171] Á. Lanas,et al. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome – a European perspective , 2006, Alimentary pharmacology & therapeutics.
[172] L. Houghton,et al. Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective , 2006, Alimentary pharmacology & therapeutics.
[173] L. Marzio,et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. , 2006, Digestive and Liver Disease.
[174] P. Scully,et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? , 2006, Gastroenterology.
[175] H. Keleş,et al. Evaluation of gallbladder motility in patients with irritable bowel syndrome. , 2005, Swiss medical weekly.
[176] D. Drossman,et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. , 2005, Gastroenterology.
[177] W. Chey,et al. Long-Term Safety and Efficacy of Alosetron in Women with Severe Diarrhea-Predominant Irritable Bowel Syndrome , 2004, The American Journal of Gastroenterology.
[178] S. Dolwani,et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology , 2004, Alimentary pharmacology & therapeutics.
[179] M. Hongo,et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome , 2004, Gut.
[180] W. Whitehead,et al. Patients and Nonconsulters with Irritable Bowel Syndrome Reporting a Parental History of Bowel Problems Have More Impaired Psychological Distress , 2004, Digestive Diseases and Sciences.
[181] H. El‐Serag,et al. Natural history of irritable bowel syndrome , 2004 .
[182] Ke-min Chen,et al. Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. , 2003, World journal of gastroenterology.
[183] A. Wald. Is Chronic Use of Stimulant Laxatives Harmful to the Colon? , 2003, Journal of clinical gastroenterology.
[184] M. Mandelkern,et al. The effect of the 5‐HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients , 2002, Alimentary pharmacology & therapeutics.
[185] W. Whitehead,et al. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? , 2002, Gastroenterology.
[186] Shara I. Feld,et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. , 2001, Gastroenterology.
[187] P. Jhingran,et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.
[188] M. Camilleri,et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. , 2001, Archives of internal medicine.
[189] I. Wiklund,et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials , 2001, Alimentary pharmacology & therapeutics.
[190] T. Poynard,et al. Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome , 2001, Alimentary pharmacology & therapeutics.
[191] A. Mangel,et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.
[192] A. Kilbourne,et al. The impact of irritable bowel syndrome on health-related quality of life. , 2000, Gastroenterology.
[193] M. Camilleri,et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial , 2000, The Lancet.
[194] D. Drossman,et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist , 1999, Alimentary pharmacology & therapeutics.
[195] A. Ishige,et al. Effects of Keishi-ka-shakuyaku-to (Gui-Zhi-Jia-Shao-Yao-Tang) on diarrhea and small intestinal movement. , 1999, Biological & pharmaceutical bulletin.
[196] A. Francavilla,et al. Otilonium bromide in irritable bowel syndrome: a double‐blind, placebo‐controlled, 15‐week study , 1998, Alimentary pharmacology & therapeutics.
[197] M. Hongo,et al. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome , 1998, Gut.
[198] A. Ishige,et al. The effects of Hange-shashin-to on the content of prostaglandin E2 and water absorption in the large intestine of rats. , 1997, Biological & pharmaceutical bulletin.
[199] M. Delvaux,et al. Trimebutine: Mechanism of Action, Effects on Gastrointestinal Function and Clinical Results , 1997, The Journal of international medical research.
[200] N. Talley,et al. Predictors of health care seeking for irritable bowel syndrome: a population based study , 1997, Gut.
[201] M. Vatn,et al. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. , 1996, Scandinavian journal of gastroenterology.
[202] U. Malt,et al. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. , 1996, Scandinavian journal of gastroenterology.
[203] G. Gasbarrini,et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. , 1995, Scandinavian journal of gastroenterology.
[204] B. Mory,et al. Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome , 1994, Alimentary pharmacology & therapeutics.
[205] E. Blanchard,et al. Relaxation training as a treatment for irritable bowel syndrome , 1993, Biofeedback and self-regulation.
[206] P. Toskes,et al. Calcium polycarbophil compared with placebo in irritable bowel syndrome , 1993, Alimentary pharmacology & therapeutics.
[207] W. Whitehead,et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. , 1992, Gut.
[208] E. Guthrie. Brief Psychotherapy with Patients with Refractory Irritable Bowel Syndrome , 1991 .
[209] C. Tanaka,et al. Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors. , 1991, Gastroenterology.
[210] G. Bensi,et al. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. , 1990, Gut.
[211] D. Jewell,et al. Food intolerance and the irritable bowel syndrome. , 1989, Gut.
[212] D. Drossman,et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. , 1988, Gastroenterology.
[213] E. Blanchard,et al. A multi-component treatment for irritable bowel syndrome , 1987 .
[214] S. Fukudo,et al. Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome. , 1987, The Tohoku journal of experimental medicine.
[215] P. Whorwell,et al. CONTROLLED TRIAL OF HYPNOTHERAPY IN THE TREATMENT OF SEVERE REFRACTORY IRRITABLE-BOWEL SYNDROME , 1984, The Lancet.
[216] A. Gupta,et al. Different therapeutic regimens in irritable bowel syndrome. , 1984, The Journal of the Association of Physicians of India.
[217] N. Read,et al. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. , 1983, Gut.
[218] J. Svedlund,et al. CONTROLLED STUDY OF PSYCHOTHERAPY IN IRRITABLE BOWEL SYNDROME , 1983, The Lancet.
[219] M. F. Brian E. Lacy PhD,et al. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis , 2018, The American Journal of Gastroenterology.
[220] P. Valle,et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. , 2018, The lancet. Gastroenterology & hepatology.
[221] R. Spiller,et al. Bowel Disorders. , 2016, Gastroenterology.
[222] 박효진. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial , 2015 .
[223] Masahiro Yoshida,et al. JSGE Clinical Practice Guidelines 2014: standards, methods, and process of developing the guidelines , 2014, Journal of Gastroenterology.
[224] F. Sung,et al. Association between irritable bowel syndrome and colorectal cancer: a nationwide population-based study. , 2014, European journal of internal medicine.
[225] K. Sugano,et al. Evidence-based clinical practice guidelines for irritable bowel syndrome , 2014, Journal of Gastroenterology.
[226] Kirsten Tillisch,et al. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. , 2011, Gastroenterology.
[227] W. Whitehead,et al. Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations , 2011, Journal of Behavioral Medicine.
[228] D. Katzka. How Does Cognitive Behavior Therapy for Irritable Bowel Syndrome Work? A Mediational Analysis of a Randomized Clinical Trial , 2008 .
[229] S. Hanauer. The role of loperamide in gastrointestinal disorders. , 2008, Reviews in gastroenterological disorders.
[230] J. Barkin. The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial , 2007 .
[231] D. Dumitrascu,et al. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome. , 2006, Romanian journal of internal medicine = Revue roumaine de medecine interne.
[232] H. El‐Serag,et al. Systemic review: Natural history of irritable bowel syndrome. , 2004, Alimentary pharmacology & therapeutics.
[233] Yosuke Kawasaki,et al. [Irritable bowel syndrome(IBS)]. , 2003, Ryoikibetsu shokogun shirizu.
[234] M. Wallander,et al. Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. , 2000, Scandinavian journal of gastroenterology.
[235] G Shaw,et al. Stress management for irritable bowel syndrome: a controlled trial. , 1991, Digestion.
[236] N. Hovdenak. Loperamide treatment of the irritable bowel syndrome. , 1987, Scandinavian journal of gastroenterology. Supplement.
[237] A. Nielsen,et al. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. , 1987, Scandinavian journal of gastroenterology. Supplement.
[238] J. Fielding. Domperidone treatment in the irritable bowel syndrome. , 1982, Digestion.
[239] K. Lüttecke. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. , 1980, Current medical research and opinion.